Amphetamine Orally Disintegrating Tablets

Another Option for the Treatment of Attention Deficit Hyperactivity Disorder

Marcia L. Buck, PharmD, FCCP, FPPAG, BCPPS


Pediatr Pharm. 2016;22(10) 

In This Article

Abstract and Introduction


The options for treatment of attention deficit hyperactivity disorder (ADHD) continue to expand (Table 1). With the approval of Adzenys XR-ODTTM on January 26, 2016, Neos Therapeutics introduced the first extended-release orally disintegrating amphetamine tablet.[1] The manufacturer also has an extended-release methylphenidate ODT in phase 3 clinical trials. The ODT form offers a convenient means of providing 10–12 hours of symptom control for patients unable to swallow tablets or capsules.